MetaVia (MTVA) Stock Price, News & Analysis

Company Overview

MetaVia, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Its work is centered on conditions such as obesity, diabetes and other disorders associated with metabolic dysfunction.

The company’s activities primarily involve the discovery, development and clinical evaluation of potential drug candidates intended to address significant unmet medical needs in metabolic health. As a development-stage biotechnology company, MetaVia’s operations are focused on research programs and advancing therapies through clinical testing rather than on commercialized products.

Publicly available information provides limited detail about MetaVia’s corporate history, geographic operations and leadership. The company is listed on the Nasdaq under the symbol MTVA.

Key Stats

• Today's Range: $1.25 to $1.43
• 50-Day Range: $1.09 to $1.84
• 52-Week Range: $0.97 to $13.42
• Volume: 33,690 shs
• Average Volume: 1.23 million shs
• Market Capitalization: $6.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Hold

MetaVia Stock Analysis - MarketRank™

MetaVia scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

MetaVia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

MetaVia has a consensus price target of $20.00, representing about 1,438.5% upside from its current price of $1.30.

Amount of Analyst Coverage

MetaVia has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MetaVia are expected to decrease in the coming year, from ($2.79) to ($3.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MetaVia is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MetaVia is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MetaVia has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.09% of the float of MetaVia has been sold short.

Short Interest Ratio / Days to Cover

MetaVia has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MetaVia has recently decreased by 43.17%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MetaVia does not currently pay a dividend.

Dividend Growth

MetaVia does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.64

News Sentiment

MetaVia has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for MetaVia this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for MTVA on MarketBeat in the last 30 days.

MarketBeat Follows

5 people have added MetaVia to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MetaVia insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.60% of the stock of MetaVia is held by insiders.

Percentage Held by Institutions

1.37% of the stock of MetaVia is held by institutions.

Company Calendar

• Today: 11/13/2026
• Last Earnings: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MTVA
• Previous Symbol: NASDAQ:NRBO
• CIK: 1638287
• Web: www.metaviatx.com
• Phone: 857-702-9600
• Fax: 734-293-0444
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MetaVia: $20.00
• High Price Target: $20.00
• Low Price Target: $20.00
• Potential Upside/Downside: +1,408.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -209.67%
• Return on Assets: -107.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.06
• Quick Ratio: 2.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.31 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 5,160,000
• Free Float: 5,133,000
• Market Cap: $6.84 million
• Optionable: N/A
• Beta: 1.24